Abvc Biopharma (ABVC) Equity Income (2018 - 2026)
Abvc Biopharma's (ABVC) quarterly Equity Income came in at -$31416.0 in Q1 2026, up 38.25% on a YoY basis from -$22723.9 in Q1 2025, and up 95.19% quarter-over-quarter from -$652979.0 in Q4 2025.
Powered by 
Analysis
Abvc Biopharma (ABVC) Equity Income (2018 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Equity Income for 7 consecutive years, with -$31416.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Equity Income rose 38.25% year-over-year to -$31416.0; the trailing twelve-month figure through Mar 2026 stood at -$783547.0 (down 100.88% YoY), and the FY2025 full-year result was -$803008.0, down 136.76% from the prior year.
- Equity Income advanced to -$31416.0 in Q1 2026 per ABVC's latest filing, from -$652979.0 in the prior quarter.
- Across five years, Equity Income topped out at -$31416.0 in Q1 2026 and bottomed at -$652979.0 in Q4 2025.
- Historically, Equity Income has averaged -$146699.4 across 3 years, with a median of -$61060.0 in 2024.
- The widest YoY moves for Equity Income: up 43.18% in 2025, down 239.69% in 2025.
- Over 3 years, Equity Income stood at -$192229.0 in 2024, then sank by 239.69% to -$652979.0 in 2025, then jumped by 95.19% to -$31416.0 in 2026.
- According to Business Quant data, Equity Income over the past three periods registered -$31416.0, -$652979.0, and -$54235.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -31,416.00 |
| Dec 31, 2025 | -652,979.00 |
| Sep 30, 2025 | -54,235.00 |
| Jun 30, 2025 | -44,917.00 |
| Mar 31, 2025 | -50,877.00 |
| Dec 31, 2024 | -192,229.00 |
| Sep 30, 2024 | -67,885.00 |
| Jun 30, 2024 | -79,057.00 |
| Dec 31, 2021 | -76,697.00 |
| Sep 30, 2021 | -91,765.00 |
| Jun 30, 2021 | -53,591.00 |
| Mar 31, 2021 | -47,791.00 |
| Dec 31, 2020 | -101,435.00 |
| Sep 30, 2020 | -887,231.00 |
| Jun 30, 2020 | -109,656.00 |
| Mar 31, 2020 | -70,411.00 |
| Dec 31, 2019 | -27,973.00 |
| Sep 30, 2019 | -64,689.00 |
| Jun 30, 2019 | -51,219.00 |
| Mar 31, 2019 | -66,205.00 |